Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04378010 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH
A Phase 2 study, sponsored by Enanta Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 98
- Enrollment target
NCT04378010 is a Phase 2 study that was terminated before completion, run by Enanta Pharmaceuticals. The registered enrollment target is 98 participants.
The verdict
NCT04378010, a Phase 2 study, was terminated before completion, sponsored by Enanta Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 98 participants
- Enrollment target
Study Summary
A randomized, double-blind study to assess the safety and efficacy of EDP-305 in subjects with liver-biopsy proven Non-Alcoholic Steatohepatitis (NASH)
Interventions
- DRUG Placebo
- DRUG EDP-305 1.5 mg
- DRUG EDP-305 2 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2020-01-27 |
| Est. Completion | 2021-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04378010
The ClinicalTrials.gov registry entry for NCT04378010 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 98 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Enanta Pharmaceuticals, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04378010 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04378010 about?
NCT04378010 is a clinical study titled "A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH". A randomized, double-blind study to assess the safety and efficacy of EDP-305 in subjects with liver-biopsy proven Non-Alcoholic Steatohepatitis (NASH)
What is the current status of trial NCT04378010?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 98 participants. The study started on 2020-01-27. Estimated completion is 2021-11-30.
What interventions are being tested in trial NCT04378010?
The interventions under investigation include: Placebo (DRUG), EDP-305 1.5 mg (DRUG), EDP-305 2 mg (DRUG).
Who is sponsoring clinical trial NCT04378010?
This trial is sponsored by Enanta Pharmaceuticals, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.